Inside the secondary analysis, the significantly less conservative but clinically meaningful criterion of stable reaction (defined being a 50% or more reduction in MADRS from baseline for two months) was used. From the patients who obtained steady response, 25.eight% inside the esketamine group and fifty seven.six% in the placebo group https://elliotti677iym5.eqnextwiki.com/user